The Medical Advisor

TL;DR  Best weight loss:  Mounjaro Best overall balance:  Wegovy Safest long-term data:  Semaglutide class Most overlooked truth:  benefits extend beyond weight Introduction: The GLP-1 Era Has Changed Medicine Over the past decade, a new class of medications— GLP-1 receptor agonists and incretin-based therapies —has fundamentally reshaped how we treat: Obesity Type 2 diabetes Cardiovascular risk Drugs like Ozempic, Wegovy, Mounjaro, and Trulicity are no longer niche therapies. They are now: Among the most prescribed metabolic drugs globally Central to what some call the “Ozempic economy” Positioned as potential lifespan-extending interventions But with rapid adoption comes confusion—and increasingly polarized narratives: One side: “These drugs are miracle breakthroughs” The other: “We don’t fully understand them—are they risky?” The truth sits in between. This guide cuts through both hype and fear to answer one question: Which GLP-1 drug is best—and what are th...

Introduction: A Turning Point in Aspirin Oncology Aspirin, originally developed by Bayer, is no longer just a cardiovascular drug being “repurposed” for cancer research. In 2025–2026, oncology entered a new phase:  a genetically stratified randomized trial showing real, clinically meaningful cancer recurrence reduction. This is best exemplified by the landmark trial published in the New England Journal of Medicine: 👉 NEJM 2025; DOI: 10.1056/NEJMoa2504650 Section 1: The NEJM 2025 Breakthrough Trial (Game-Changing Evidence) Trial Overview A double-blind, placebo-controlled randomized trial evaluated aspirin in patients with resected colorectal cancer carrying PI3K pathway alterations. Key design features: Population: Stage I–III colorectal cancer Biomarker selection: PI3K pathway mutations (including PIK3CA, PIK3R1, PTEN) Intervention: Aspirin 160 mg daily vs placebo Duration: 3 years Endpoint: Cancer recurrence 📄 Full trial: https://pubmed.ncbi.nlm.nih.gov/40961426/ Key Results Pr...

Aspirin is a staple in medicine cabinets worldwide, known primarily for its pain-relieving and anti-inflammatory properties. However, recent research is shedding light on a potentially game-changing role for this common medication: cancer prevention and treatment. (1) While aspirin's anticancer properties have been hinted at in various studies over the years (2), this function has largely been overlooked in favor of newer, more expensive drugs. Now, groundbreaking experiments are not only reaffirming aspirin's potential in fighting cancer but also uncovering a more potent analog that could revolutionize our approach to cancer treatment. This forgotten function of aspirin, and its even more powerful cousin, may offer new hope in the battle against one of humanity's most persistent health challenges. Let's explore the exciting developments that are causing researchers to take a fresh look at this familiar drug. Aspirin and Cancer: Introducing 2,6-Di...

Semaglutide, known by the brand names Ozempic, Wegovy, Rybelsus and others, is the latest weight-loss craze to hit Hollywood and beyond. The prescription drug, which is administered via a weekly injection, is intended to treat Type 2 diabetes, but it’s widely used off-label for weight loss. They all belong to the same medication class — glucagon-like peptide-1 (GLP-1) agonists ( GLP-1 receptor agonists ).  GLP-1 agonists work by triggering insulin release, blocking sugar production in your liver, and making you feel full. But with all of these brands out there, how do you decide which is right for you? Let’s get to know some of the differences between these major GLP-1 agonist drugs. A 2021 study funded by Novo Nordisk, the drug’s maker, found using semaglutide once a week led to a 14.9% reduction in body weight among adults with obesity. There’s been such a rush on the drugs that the U.S. Food and Drug Administration lists both Ozempic and Wegovy a...

Abstract Background: Advanced prostate cancer, including metastatic hormone-sensitive and castration-resistant forms, often develops resistance to standard androgen deprivation therapies, highlighting the need for novel adjunctive strategies. Repurposed antiparasitic agents such as fenbendazole and ivermectin have garnered attention for their potential anticancer properties, supported by preclinical studies demonstrating microtubule disruption, apoptosis induction, and metastasis inhibition. Methods: This compilation reviews 123 case reports from 2024–2026, sourced from peer-reviewed publications, social media platforms, and personal testimonials. Protocols typically involved fenbendazole (222–2000 mg/day) and ivermectin (1–2 mg/kg/day), often combined with adjuncts l...